| Disease | DISCUSSION OF A CLINICAL TRIAL FOR THE TITLE COMPOUND. NUMBER OF SUBJECTS WILL BE 49. STARTING DATE WILL BE APRIL 1989. TREATMENT DURATION WILL BE ORALLY FOR 4 WEEKS.
STUDIES AT HARVARD MEDICAL SCHOOL(BOSTON),NORTHWESTERN UNIVERSITY MEDICAL CENTER(CHICAGO),STANFORD UNIVERSITY MEDICAL CENTER(STANFORD),UNIVERSITY CALIFORNIA MEDICAL CENTER(SAN DIEGO) AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE(ST.LOUIS).
DOSING WILL ESCALATE FROM 2 MGM/KG 4 TIMES DAILY. EXCLUSION CRITERIA: AZT OR ANTIRETROVIRAL DRUGS MORE THAN 30 DAYS PRIOR TO ENROLLMENT, CLINICALLY SIGNIFICANT DIARRHEA.
INCLUSION CRITERIA: PLATELETS GREATER THAN 100,000, SGOT/PT LESS THAN 3 X NORMAL, CREATININE LESS THAN 1.5, BILIRUBIN LESS THAN 3 X NORMAL, GRANULOCYTES MORE THAN 1000, AGE GREATER THAN 12. |